<h4>Objectives</h4>Primary Objective • To evaluate the effect of ravulizumab, a long-acting complement (C5) inhibitor plus best supportive care (BSC) compared with BSC alone on the survival of patients with COVID-19. The gene discussed is C5; the disease is COVID-19.